Vestibular migraine (VM) is one of the most common vestibular disorders, affecting 1.0% to 2.7% of the general population1, 7% of patients with definite migranous vertigo in dizziness clinics2, as well as 10.3% of VM patients in headache clinics3; 65% to 85% of VM patients are female1. Despite the relative prevalence of vestibular migraine, evidence-based medicine remains scarce. Two Cochrane reviews published in 2023 found that there is almost no evidence to support the use of medications for the acute treatment or preventive treatment of VM4,5.
Calcitonin gene-related peptide (CGRP) has been established as an excellent target for the treatment of migraine. Animal studies suggest a link between CGRP and vestibular disorders. A prospective observational cohort study found that monoclonal antibodies targeting CGRP receptors and ligands were very effective for vestibular migraine (VM), with 90% of participants experiencing at least a 50% reduction in vertigo attacks6. A small-scale prospective randomized controlled trial showed that a monoclonal antibody targeting a CGRP ligand significantly reduced the number of dizziness days per month in VM patients compared to placebo7. The efficacy of CGRP small molecule antagonists for the preventive and acute treatment of migraines has been widely recognized8,9. Therefore, we speculate that Rimegepant is effective for the preventive and acute treatment of vestibular migraine.
By focusing on a large sample RCT, our study can offer new evidence-based treatment options for patients with vestibular migraine. This is crucial, as many patients with vestibular migraine may not respond well to conventional migraine treatments. Our findings could guide clinicians in choosing more effective therapeutic strategies.
Specifically in acute treatment of vestibular migraine, triptans have failed to show superiority when compared to placebo in treatment vestibular migraine symptoms10. Prochlorperazine, a vestibular sedative, is widely used for acute treatment of vestibular migraine but is known to chronify symptoms11. Should rimegepant demonstrate superiority to placebo in this study, rimegepant could potentially become the first-line treatment for vestibular migraine across the world.

Start Date01 Apr 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT06641466

/ Not yet recruitingPhase 3

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Start Date21 Feb 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06728345

/ Not yet recruitingNot ApplicableIIT

The Real-world Study of Rimegepant for the Preventive Treatment in Female Migraine Patients

The goal of this observational study is to learn about the effects and safety of Rimegepant in women, especially young and middle-aged women, who take Rimegepant to treat their migraine in the real world. Participants already taking Rimegepant (75mg QOD) as their regular preventive treatment of migraine for 12 weeks will be evaluated as the followings :
1. To evaluate the change from baseline in the mean number of migraine days per month during weeks 1-12
2. To evaluate the number of participants that have least a 50% reduction from baseline in the mean number of migraine days per month during weeks 1-12

Start Date01 Dec 2024

Sponsor / Collaborator

The First Affiliated Hospital of Soochow University

100 Clinical Results associated with Rimegepant Sulfate

100 Translational Medicine associated with Rimegepant Sulfate

100 Patents (Medical) associated with Rimegepant Sulfate

247

Literatures (Medical) associated with Rimegepant Sulfate

01 Feb 2025·Pain and Therapy

Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study

Article

Author: Hutchinson, Susan ; Kudrow, David ; Fullerton, Terence ; Pixton, Glenn C. ; Pixton, Glenn C

INTRODUCTION:

Anxiety and depression are frequently associated with migraine, and antidepressant use can complicate treatment. These analyses assessed the safety and tolerability of rimegepant in participants with migraine and anxiety and/or depression, or using selective serotonin reuptake inhibitors (SSRIs) and/or other antidepressants.

METHODS:

Data were from a phase II/III safety study of rimegepant for the acute treatment of migraine. Participants with a history of 2-14 migraine attacks per month of moderate or severe pain intensity self-administered rimegepant 75 mg as needed up to once daily for up to 52 weeks. These post hoc subgroup analyses assessed safety according to self-reported history of anxiety (yes or no) or depression (yes or no), and current use of SSRIs (yes or no) or other antidepressants (yes or no).

RESULTS:

Of 1800 treated participants, 23.2% (n = 417) had a self-reported history of anxiety, 23.7% (n = 426) had a self-reported history of depression, and 11.2% (n = 202) reported both anxiety and depression. A total of 10.1% (n = 181) of participants were using an SSRI, 10.8% (n = 195) were using other antidepressants, and 1.8% (n = 32) were using both. Across the subgroups with anxiety, without anxiety, with depression, without depression, using SSRIs, not using SSRIs, using other antidepressants, and not using other antidepressants, respectively, similar proportions of participants reported adverse events (67.1%, 58.4%, 62.0%, 60.0%, 64.1%, 60.0%, 66.2%, 59.8%), serious adverse events (3.6%, 2.3%, 2.8%, 2.5%, 3.3%, 2.5%, 5.1%, 2.3%), and discontinuation of rimegepant due to adverse events (4.1%, 2.2%, 3.1%, 2.5%, 5.0%, 2.4%, 3.1%, 2.6%). Numerical improvements in a variety of participant-reported outcomes were also observed at weeks 12 and 52.

CONCLUSIONS:

Rimegepant showed favorable safety and tolerability in adults with migraine and a history of anxiety and/or depression and with SSRI and/or other antidepressant use.

TRIAL REGISTRATION:

Clinicaltrials.gov: NCT03266588.

01 Feb 2025·HEADACHE

Characterization of rimegepant drug–drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam

Article

Author: Croop, Robert ; Matschke, Kyle T. ; Bhardwaj, Rajinder ; Liu, Jing ; Morris, Beth ; Bertz, Richard

Abstract:

Objective:

Reported here are the results of four rimegepant phase I studies, in healthy participants, aimed at determining the in vivo potential of rimegepant (75 mg) for cytochrome P450 (CYP) 3A4‐related drug–drug interactions (DDIs).

Background:

Rimegepant orally disintegrating tablet (Pfizer Inc., New York, NY, USA) is a calcitonin gene‐related peptide receptor antagonist approved for acute treatment of migraine and preventive treatment of episodic migraine. People with migraine commonly use multiple drug treatments, with the potential for DDIs.

Methods:

Each study was an open‐label, single‐arm, single‐sequence, crossover study. Rimegepant was tested as a victim drug by separate co‐administration of itraconazole (a strong CYP3A4 inhibitor and P‐glycoprotein inhibitor) in Study 1, rifampin (a strong CYP3A4 inducer and moderate CYP2C9 inducer) in Study 2, and fluconazole (a strong CYP2C9 inhibitor and moderate CYP3A4 inhibitor) in Study 3, and as a perpetrator drug by co‐administration with midazolam (a CYP3A4 substrate) in Study 4.

Results:

Mean values of single‐dose rimegepant maximum concentration (Cmax) and area under the curve from time 0 to infinity (AUC0–inf) increased with itraconazole co‐administration (n = 22) by 1.42‐fold (90% confidence interval [CI] 1.25–1.61) and by 4.14‐fold (90% CI 3.87–4.44), respectively, and decreased with rifampin co‐administration (n = 21) to 36% (90% CI 31.2–41.4%) and to 19% (90% CI 16.3–21.4%), respectively. Co‐administration with fluconazole (n = 23) increased rimegepant mean AUC0–inf by 1.80‐fold (90% CI 1.68–1.93), with no impact on Cmax (1.04‐fold; 90% CI 0.94–1.15). Co‐administration of rimegepant single dose (300 mg; n = 14) or multiple doses (150 mg/day; n = 14) increased the mean Cmax of midazolam by 1.38‐fold (90% CI 1.13–1.67) and 1.53‐fold (90% CI 1.32–1.78), respectively, and the AUC0–inf of midazolam by 1.86‐fold (90% CI 1.58–2.19) and 1.91‐fold (90% CI 1.63–2.25), respectively.

Conclusions:

Based on the magnitude of DDIs, these studies indicate the following: co‐administration of rimegepant with a strong CYP3A4 inhibitor should be avoided; during co‐administration with a moderate CYP3A4 inhibitor, another dose of rimegepant within 48 h should be avoided; co‐administration of rimegepant with a strong or moderate CYP3A4 inducer should be avoided; CYP2C9 does not play a meaningful role in rimegepant metabolism; and there is no clinically meaningful CYP3A4 inhibition by rimegepant.

01 Feb 2025·ADVANCES IN THERAPY

US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review

Article

Author: Krasenbaum, Lynda J ; Carr, Karen ; Driessen, Maurice T ; Saikali, Nicolas P ; Eugeni, Patrick ; Niu, Zhongzheng ; Seminerio, Michael J ; McVige, Jennifer W ; Rooney, Megan E

INTRODUCTION:

Fremanezumab, a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway, and gepants, small molecule CGRP receptor antagonists, are both approved for the treatment of migraine or its symptoms. This study assessed effectiveness, tolerability, and migraine-related healthcare resource utilization (HCRU) after the addition of fremanezumab for preventive migraine treatment in patients using gepants for acute treatment.

METHODS:

Data were extracted during a retrospective chart review from electronic medical records from the Dent Neurologic Institute. Eligible patients were ≥ 18 years old, using gepants (rimegepant or ubrogepant), who initiated fremanezumab between January 1, 2020, and May 1, 2021 (index date: date of fremanezumab initiation) and continued concomitant use of gepants and fremanezumab for ≥ 1 month (post-index; between 7-9 months of follow-up). Outcomes included monthly migraine days (MMD), adverse events (AEs), reasons for discontinuation, and migraine-related HCRU.

RESULTS:

A total of 55 patients [female, 93%; mean (SD) age, 43.5 (13.5) years] met the inclusion criteria. All patients were diagnosed with chronic migraine. Patients had an average (SD) MMD of 15.8 (7.4) at the index date. Average (SE) change in MMD from index date to post-index was - 6.5 (1.0) days (p < 0.0001). Five patients (9.1%) experienced AEs post-index; no serious AEs (SAEs) were reported. The number of migraine-related medications used decreased from the index date to post-index by a mean of 0.6 for preventive medications (p = 0.070), and 0.8 for acute medications (p = 0.050). The number of outpatient office-based visits also decreased [mean (SD): 6 months pre-index, 5.8 (4.4) vs. 6 months post-index, 4.1 (4.0); p < 0.0001].

CONCLUSION:

The addition of fremanezumab preventively to gepants for acute migraine treatment was effective, resulted in fewer outpatient office visits, and yielded no SAEs or AEs that were novel to these migraine medication classes.

News (Medical) associated with Rimegepant Sulfate

06 Feb 2025

·www.echemi.com

Pfizer Reports 2024 Earnings with $63.6 Billion Revenue and Concerns Over Innovation

On February 4, Pfizer announced its financial results for the fourth quarter and the entire year of 2024, revealing a total revenue of $63.6 billion, a 7% increase year-on-year. The fourth quarter alone saw revenues of $17.8 billion, reflecting a substantial 22% growth compared to the same period last year. However, the net profit for the year was $8.031 billion, with only $410 million generated in the fourth quarter, raising concerns among investors. Pfizer operates through three main business segments: Generic Medicines, Specialty Medicines, and Oncology. The Generic Medicines division reported annual revenues of $30.135 billion, a 2% decline from the previous year. In contrast, the Specialty Medicines segment achieved $16.652 billion in revenue, marking an 11% increase, while the Oncology division saw a 25% rise in revenue, totaling $15.612 billion. In the Generic Medicines segment, sales of the COVID-19 vaccine reached $5.353 billion, down 52% year-on-year. Despite this significant drop, there is no indication that the vaccine has fallen out of favor. Sales of apixaban totaled $7.366 billion, up 9%, although this product is nearing the end of its lifecycle. The pneumonia vaccine family generated $6.411 billion, a slight 1% decline. Notably, sales of Rimegepant, an oral CGRP inhibitor, surged to $1.263 billion, a 36% increase from 2022. The RSV bivalent vaccine Abrysvo brought in $755 million, down approximately $150 million from the previous year. Other pipeline products primarily consist of Pfizer's mature offerings, which generally experienced declines. In the Specialty Medicines sector, the drug Vyndaqel for transthyretin amyloidosis proved to be a significant revenue generator, contributing $5.411 billion in sales, a remarkable 64% increase. However, sales of tofacitinib fell 31% to $1.168 billion due to patent cliffs affecting the immediate-release formulation. The older drug ilaprazole saw sales of $690 million, down 17% year-on-year. Surprisingly, the antibiotic sufentanil still managed to generate $637 million in sales, despite a 4% decline, with a significant portion likely coming from China. The injectable ceftazidime-avibactam (Sivextro) achieved $586 million in sales, a 16% decline, marking it as the first cephalosporin antibiotic to surpass $500 million in sales since 2010. In the Oncology division, palbociclib generated $4.367 billion, down 8% year-on-year. Enzalutamide saw revenues of $2.039 billion, a 23% increase. The new drug padcev (enfortumab vedotin) performed exceptionally well, achieving $1.588 billion in sales during its first full fiscal year. Adcetris (brentuximab vedotin) also showed strong performance, with sales soaring to $1.089 billion. Axitinib generated $978 million, down 6%, while bosutinib remained stable at $645 million. Despite maintaining its position as the world's largest pharmaceutical company, Pfizer faces significant challenges regarding innovation and pipeline development. As of December 2024, the company's market capitalization stood at $150 billion, significantly lower than competitors such as Eli Lilly ($750 billion), Johnson & Johnson ($350 billion), AbbVie ($320 billion), Novo Nordisk ($300 billion), Merck ($250 billion), Roche ($220 billion), Novartis ($210 billion), and AstraZeneca ($200 billion). The pressure to innovate and expand its product pipeline remains a critical concern for Pfizer moving forward.

VaccineFinancial StatementDrug ApprovalClinical ResultBiosimilar

30 Dec 2024

·www.prnewswire.com

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP. "We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized myasthenia gravis and CIDP patients," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We look forward to VYVDURA being a new treatment option for an even broader number of patients in Japan." The MHLW approval is based on the ADHERE Study, the largest clinical trial to date studying CIDP. In the ADHERE study, 69% (221/322) of patients treated with VYVDURA, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. Ninety-nine percent of trial participants elected to participate in the ADHERE+ open-label extension. The safety results were generally consistent with the known safety profile of VYVDURA in previous clinical studies and real-world use. VYVDURA was also approved by the MHLW for manufacturing and marketing in January 2024 and launched in April 2024 for the treatment of generalized myasthenia gravis (gMG). In March 2024, VYVDURA was designated as an Orphan Drug for the treatment of CIDP by the MHLW. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including offering flexibility to receive treatment in more convenient locations and broadening the treatment options for the indications referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugClinical Result

30 Oct 2024

·www.pharmaceutical-technology.com

Pfizer boasts over 30% increase in Q3 revenues against previous year

Pfizer CEO Dr Albert Bourla presided over an exceptional Q3 amid financial decline and pressure from investor Starboard Value. Credit: Ververidis Vasilis / Shutterstock. Pfizer has reported strong revenues in its latest earnings report, noting increased revenues over Q3 2023 largely due to sales from the company’s Covid-19 drugs Paxlovid and Comirnaty. In the 29 October report, Pfizer stated overall revenues in Q3 2024 had risen by 31% compared to the same quarter in the previous year, amounting to an additional $4.3bn. Of the total $17.7bn in Q3 revenues, $2.7bn and $1.4bn were derived from sales of Paxlovid and Comirnaty, respectively, which together accounted for almost half of the company’s year-over-year growth. The robust Q3 report did little to affect share price, although traded share volume rose to a level unseen since the company acquired Seagen in December 2023. Pfizer’s market cap is currently $161bn. This month has also seen disruption to the company’s management, as activist hedge fund Starboard Value took a $1bn stake in Pfizer, equivalent to 0.6% of the company at the time of purchase. Aiming to steer a turnaround in Pfizer’s fortunes, Starboard accused company executives of “ coercive conduct ” against former CEO Ian Read and former CFO Frank D’Amelio who retracted support after initially supporting the fund’s plans. In the Q3 conference call, Pfizer CEO Albert Bourla stated: “While we agree with some of the points [Starboard] raised, we have vastly different views on many others.” See Also: How a patient helped shape a treatment for rare skin disorder ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing He noted common dissatisfaction with shareholder return, but disagreed with Starboard’s challenge of Pfizer’s capital deployment, saying the company’s deals with Seagen and BioNTech “have been transformational for Pfizer”. Nonetheless, Bourla said some changes have been made at Pfizer this year to address Starboard’s such as separating US and international business and restructuring company management. The 31% Q3 growth over Q3 2023 was in sharp contrast to the overall growth of 2% for the first nine months of 2024 compared to those of 2023. Consequently, Pfizer has adjusted its financial guidance, raising projected revenues for 2024 to between $61bn and $64bn, up $1.5bn from estimates made in the company’s Q2 statement. This includes estimated sales of $5bn and $5.5bn from Comirnaty and Paxlovid, respectively, bringing the full year’s expected growth to 9% to 11% over 2023. Pfizer also attributed upticks in 2024 Q3 revenue to $854m in quarterly sales due to its acquisition of Seagen. Alongside this were increased operational revenues of 9% for Eliquis (apixaban), 28% for Xtandi (enzalutamide), 45% for Vydura (rimegepant sulfate), and 63% for Pfizer’s Vyndagel family (tafamidis) against equivalent quarterly revenues the previous year. Some drug-specific revenues did see decreases. Namely, revenues for Xeljanz (tofacitinib citrate) were down 35% and decreased by 12% for Ibrance (palbociclib) compared to Q3 2023. Drops in sales were attributed to label changes, lowered US net price, and expiry of exclusivity in Canada for Xeljanz, as well as competitive pressure and international price decreases for Ibrance. Bourla and Pfizer CFO David Denton gave statements attributing the company’s strong Q3 in part to ongoing cost reduction efforts and heightened demand for Paxlovid during the recent wave of Covid-19.

AcquisitionFinancial StatementIPO

100 Deals associated with Rimegepant Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Rimegepant Sulfate	N02C	DB12457

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	US	Pfizer Inc.	27 Feb 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine Without Aura	Phase 3	-	Pfizer Inc.	21 Feb 2025
Temporomandibular Joint Disorders	Phase 3	US	Pfizer Inc.	05 May 2022
Chronic rhinosinusitis with nasal polyps	Phase 3	US	Pfizer Inc.	17 Feb 2022
Nasal Polyps	Phase 3	US	Pfizer Inc.	17 Feb 2022
Migraine With Aura	Phase 3	US	Pfizer Inc.	28 Apr 2021
Migraine With Aura	Phase 3	PL	Pfizer Inc.	28 Apr 2021
Migraine With Aura	Phase 3	ES	Pfizer Inc.	28 Apr 2021
Acute migraine	Phase 3	CN	Pfizer Inc.	22 Oct 2020
Acute migraine	Phase 3	CN	Bioshin Ltd.	22 Oct 2020
Acute migraine	Phase 3	KR	Bioshin Ltd.	22 Oct 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05399459 (CTgov)	Phase 3	Migraine Disorders	897	Rimegepant 25 MG (Rimegepant 25 mg)	qpfvzdduqw(bewuqtylhw) = cpumrykhed lntelbhoup (fpzmbnwwdg, wgnziattfi - sznnfapopf) View more	-	10 Feb 2025
				Rimegepant 75 MG (Rimegepant 75 mg)	qpfvzdduqw(bewuqtylhw) = qptptbyzmt lntelbhoup (fpzmbnwwdg, xjazmuigrl - efruxrbeba) View more
NCT03266588 (phase II/III safety study of rimegepant, Pubmed \| Pain Ther)	Phase 2/3	anxiety \| depression \| SSRIs ... View more	1,800	Rimegepant 75 mg	ujfshqmyyr(ejroyzbyxp) = qmgkdrzuqd sjfjtrmoph (anwqhcvzhd ) View more	Positive	09 Nov 2024
				Placebo	ujfshqmyyr(ejroyzbyxp) = bzbxvxhfus sjfjtrmoph (anwqhcvzhd ) View more
NCT03266588 (Pubmed) Manual	Phase 2/3	Migraine Disorders	1,800	Rimegepant 75 mg	gnmwhollax(sbwzeypykf) = hfroplcbng avjbvexqps (dbzlfqpmuk ) View more	Positive	10 Jul 2024
				Rimegepant (CV risk 1)	gnmwhollax(sbwzeypykf) = qkzoqnxzww avjbvexqps (dbzlfqpmuk ) View more
NCT03235479 (Pubmed) Manual	Phase 3	Migraine Disorders	1,162	Rimegepant 75 mg oral tablet	skgouxlufp(ibqepqidui) = gtpzolhidv ylslvbahat (nlhgjdvlym ) View more	Positive	01 Jul 2024
				Placebo	skgouxlufp(ibqepqidui) = pyofrzieoh ylslvbahat (nlhgjdvlym ) View more
NCT03941834 (BHV3000-202, CTgov)	Phase 2	Trigeminal Neuralgia	65	Rimegepant (DBT Phase: Pooled Rimegepant)	ldgqobmhxt(vpncgmrjsn) = pfeasiawtv fajadptbek (emffajcqbn, xomfuspdxa - knqkydhvkn) View more	-	10 Jun 2024
				placebo+rimegepant (DBT Phase: Pooled Placebo)	ldgqobmhxt(vpncgmrjsn) = qhcephkmyi fajadptbek (emffajcqbn, dyqwbudvza - slfabxqibo) View more
NCT05262517 (CTgov)	Phase 3	Temporomandibular Joint Disorders	126	Rimegepant (BHV3000 (Rimegepant (BHV3000))	cpgumjptgz(riyfsmezub) = iroseglhxo wchjiercjj (dhsxlpgpbi, hahqkbhcdk - wrvolpmaow) View more	-	16 May 2024
				placebo+rimegepant (Placebo)	cpgumjptgz(riyfsmezub) = rpzqwncgzq wchjiercjj (dhsxlpgpbi, olylvrjfby - gghhzbnnrb) View more
NCT04574362 (Pubmed) Manual	Phase 3	Acute migraine	1,075	Rimegepant ODT 75 mg	rpvcukipjf(floyioqpjh) = rkspeklkse ebatojqvhu (bypqwvuaat ) View more	Positive	16 Apr 2024
				Placebo	rpvcukipjf(floyioqpjh) = wlvltkwuyb ebatojqvhu (bypqwvuaat ) View more
AAN2024	Not Applicable	Migraine Disorders	-	Rimegepant	eqtowdurxu(bthdfdeelr) = vpevwxaxjh mtqtnjcjdt (ymqyebftee, 56.0%–60.2%) View more	-	09 Apr 2024
				Zavegepant	eqtowdurxu(bthdfdeelr) = zpsligjgck mtqtnjcjdt (ymqyebftee, 56.4%–62.5%) View more
P7-12.010 (AAN2024)	Not Applicable	Migraine Disorders CGRP	10	Rimegepant	dpmejydnhi(jmlurubfxy) = other had dyspepsia tqyeawmrfi (vqgepsgllx ) View more	Positive	09 Apr 2024
NCT03266588 (Pubmed \| Cephalalgia) Manual	Phase 2/3	Migraine Disorders calcitonin gene-related peptide receptor	1,800	Rimegepant 75 mg PRN 2-8	oifdnlcbiu(nabpjvvfox) = upper respiratory tract infection (8.8%), nasopharyngitis (6.8%) and sinusitis (5.1%). Most AEs were mild or moderate and considered unrelated to rimegepant. lvuljhvusa (kuikqsarue ) View more	Positive	01 Apr 2024
				Rimegepant 75 mg PRN 9-14

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis